Atossa Therapeutics Announces Year End 2020 Financial Results and Provides Corporate Update

Atossa logo

 View All
Atossa Therapeutics Announces Year End 2020 Financial Results and Provides Corporate Update

SEATTLE, March 31, 2021 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announced financial results for the fiscal year ended December 31, 2020, and provided an update on recent company developments.

Key recent developments and from Q4 2020 include:

  • Demonstrated positive interim results of the Company’s open-label Phase 2 clinical study of oral Endoxifen administered in the “window of opportunity” between diagnosis of breast cancer and surgery and, based on those results, Atossa concluded the study early and is accelerating its Endoxifen program in the United States
  • Announced updated findings following 24 months of an Expanded Access (or “compassionate use”) single-patient study of Endoxifen. The patient in the study had no cancer recurrence and suffered no side effects. Endoxifen did not cause other safety and tolerability concerns in this patient
  • Received a “Safe to Proceed” letter from the FDA permitting the use Atossa’s oral Endoxifen as a treatment in an ovarian cancer patient (expanded access)
  • Announced final results from its Phase 1 double-blinded, randomized, placebo-controlled clinical study using Atossa’s proprietary drug candidate AT-301 administered by nasal spray. AT-301 was considered to be safe and well tolerated in healthy male and female participants in this study at two different dose levels over 14 days. AT-301 is being developed for at home use for patients recently diagnosed with COVID-19
  • Completed financing transactions with net proceeds of approximately $136 million in December 2020 and Q1 2021

“We believe that in 2020 Atossa rose to meet the challenges of a pandemic through innovation and rapid response to the global events impacting economies, institutions, and pharmaceutical research and development,” said Dr. Steven Quay, Atossa’s President and Chief Executive Officer. “Despite these challenges, 2020 was the year our proprietary Endoxifen programs began to show the potential breadth and depth of its medical and ultimate commercial value. Three recent Endoxifen-related events stand out:

  • the reporting of two-year experience in the adjuvant setting in breast cancer in a single patient, Expanded Access study in which Endoxifen was well tolerated and cancer recurrence was not seen clinically;
  • the better-than-expected response in the breast cancer window-of-opportunity study, allowing that study to be closed early based on success, accelerating that program almost one year; and
  • the initiation of an Expanded Access treatment program in an ovarian cancer patient, based on sensitivity to Endoxifen of laboratory cancer organoids from this patient.

“Our nasal spray AT-301 being developed for COVID-19 patients to use at home showed encouraging results in preclinical and Phase 1 studies. We believe that AT-301 has the potential to provide an important and necessary component of a broader global response to COVID-19. Although it is encouraging that traditional vaccines are becoming available, there are many people who won’t take a vaccine, and current vaccines may not protect against future variants.

“Finally, the ability to strengthen our balance sheet over the last few months, even in these challenging times, places Atossa in a good position to execute on business opportunities, both internal and potentially external, during the remainder of 2021 and beyond,” concluded Dr. Quay.

Year Ended December 31, 2020 Financial Results 

For the year ended December 31, 2020, Atossa has no source of sustainable revenue and no associated cost of revenue.

Operating Expenses
Total operating expenses were $14,607,000 for the year ended December 31, 2020, which is a decrease of $2,658,000 or 15%, from the year ended December 31, 2019. Operating expenses for 2020 consisted of research and development (“R&D”) expenses of $6,608,000 and general and administrative (“G&A”) expenses of $7,999,000. Operating expenses for 2019 consisted of R&D expenses of $6,645,000, and G&A expenses of $10,620,000.

Research and Development Expenses
R&D expenses for the year ended December 31, 2020, were $6,608,000, a decrease of $37,000 or 1% from total R&D expenses in 2019 of $6,645,000. The decrease in R&D expense is attributed primarily to a decrease in stock-based compensation of approximately $2,214,000, which is a non-cash charge, offset by an increase in salaries of approximately $428,000, and an increase in professional fees and clinical trials expenses of approximately $1,696,000, as compared to the same period in 2019. We expect our R&D expenses to increase into 2021 as Atossa seeks to commence a study of AT-H201, complete a preclinical and commence a clinical study of AT-301, launch a Phase 2 clinical trial of Endoxifen in women with high breast density, and continue the development of other indications and therapeutics.

General and Administrative Expenses
G&A expenses were $7,999,000 for the year ended December 31, 2020, a decrease of $2,621,000, or 25% from the total G&A expenses for the year ended December 31, 2019, of $10,620,000. The decrease in G&A expenses for the year ended December 31, 2020, is mainly attributed to a decrease in stock-based compensation of approximately $3,610,000, which is a non-cash charge, offset by an increase in legal fees of approximately $507,000, professional fees of approximately $169,000 and insurance costs of approximately $268,000 compared to the same period in 2019. G&A expenses consist primarily of personnel and related benefit costs, facilities, professional services, insurance, and public company related expenses.

As of December 31, 2020, the Company had cash, cash equivalents and restricted cash of $39.7 million.

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious diseases with a current focus on breast cancer and COVID-19. For more information, please visit

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Company Contact:
Atossa Therapeutics, Inc.
Kyle Guse CFO and General Counsel
Office: (866) 893-4927

Investor Relations Contact:
Core IR
Office: (516) 222-2560

Source: Atossa Therapeutics, Inc.


    As of December 31,  
Assets   2020     2019  
Current assets                
Cash and cash equivalents   $ 39,553,671     $ 12,581,136  
Restricted cash     110,000       110,000  
Prepaid expenses     1,813,902       862,344  
Research and development tax rebate receivable     634,940       739,656  
Other current assets     657,662       26,130  
Total current assets     42,770,175       14,319,266  
Furniture and equipment, net     20,632       34,350  
Intangible assets, net     13,375       68,542  
Right-of-use asset     18,053       50,479  
Other assets     17,218       17,218  
Total Assets   $ 42,839,453     $ 14,489,855  
Liabilities and Stockholders’ Equity                
Current liabilities                
Accounts payable   $ 1,588,613     $ 293,171  
Accrued expenses     93,367       77,888  
Payroll liabilities     963,665       899,420  
Common stock warrant liability     13,003,075        
Lease liability     18,053       39,371  
Other current liabilities     4,748       12,892  
Total current liabilities     15,671,521       1,322,742  
Long term liabilities                
Lease liability long term           11,108  
Total Liabilities     15,671,521       1,333,850  
Commitments and contingencies                
Stockholders’ equity                
Preferred stock – $0.001 par value; 10,000,000 shares authorized; 621 and 671 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively     1       1  
Additional paid-in capital – Series B convertible preferred stock     620,999       670,999  
Common stock – $0.18 par value; 175,000,000 shares authorized; 47,548,835 and 9,130,984 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively     8,558,778       1,643,565  
Additional paid-in capital     129,887,146       104,912,480  
Accumulated deficit     (111,898,992 )     (94,071,040 )
Total Stockholders’ Equity     27,167,932       13,156,005  
Total Liabilities and Stockholders’ Equity   $ 42,839,453     $ 14,489,855  


    For the Year Ended December 31,  
    2020     2019  
Operating expenses                
Research and development   $ 6,608,392     $ 6,645,417  
General and administrative     7,999,000       10,620,008  
Total operating expenses     14,607,392       17,265,425  
Operating loss     (14,607,392 )     (17,265,425 )
Change in fair value of common stock warrants     (2,332,567 )      
Warrant financing expense     (938,794 )      
Other income     50,801       25,648  
Loss before income taxes     (17,827,952 )     (17,239,777 )
Income taxes            
Net loss   $ (17,827,952 )   $ (17,239,777 )
Deemed dividend attributable to preferred stock     (4,502,799 )      
Net loss applicable to common shareholders   $ (22,330,751 )   $ (17,239,777 )
Loss per common share – basic and diluted   $ (1.97 )   $ (2.03 )
Weighted average shares outstanding – basic and diluted     11,308,532       8,496,964  


Primary Logo

Mar 31, 2021